Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – Should You Sell?

Dyadic International Inc. (NASDAQ:DYAI)’s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.94 and traded as low as $0.85. Dyadic International shares last traded at $0.89, with a volume of 33,590 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DYAI. Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Monday, December 29th. HC Wainwright assumed coverage on Dyadic International in a research note on Thursday, October 23rd. They issued a “buy” rating and a $3.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Stock Up 1.2%

The company has a 50-day moving average of $0.94 and a 200-day moving average of $0.99. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.92. The company has a market capitalization of $32.21 million, a price-to-earnings ratio of -3.71 and a beta of 1.26.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.22 million. Dyadic International had a negative return on equity of 537.31% and a negative net margin of 221.09%. On average, equities analysts predict that Dyadic International Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

Several institutional investors and hedge funds have recently made changes to their positions in DYAI. Bank of America Corp DE grew its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Marathon Capital Management acquired a new stake in Dyadic International during the 3rd quarter worth about $41,000. AlphaCore Capital LLC purchased a new stake in Dyadic International during the 2nd quarter valued at about $50,000. Landscape Capital Management L.L.C. purchased a new stake in Dyadic International during the 3rd quarter valued at about $190,000. Finally, Truist Financial Corp increased its holdings in shares of Dyadic International by 30.5% in the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the period. 27.95% of the stock is currently owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.